Decontamination: major variables create nightmare for companies
This article was originally published in Clinica
Executive Summary
The information manufacturers must give to purchasers about how to decontaminate their products may appear relatively straightforward, according to the text of the medical device directives. But this a very complex area, where the unexpected often happens and only a deeper understanding of the full implications for reprocessors and users will help medical device manufacturers really offer what their market wants and win popularity against other products on the market.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.